Progress in translational research on immunotherapy for osteosarcoma
10.3969/j.issn.1674-8115.2024.07.002
- VernacularTitle:骨肉瘤免疫微环境及其免疫治疗临床转化研究进展
- Author:
Fei HU
1
;
Xiaohan CAI
;
Rui CHENG
;
Shiyu JI
;
Jiaxin MIAO
;
Yan ZHU
;
Guangjian FAN
Author Information
1. 上海交通大学医学院附属仁济医院骨关节外科,上海 200001
- Keywords:
osteosarcoma;
tumor immune microenvironment(TIME);
immunotherapy;
clinical translation
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2024;44(7):814-821
- CountryChina
- Language:Chinese
-
Abstract:
Osteosarcoma is a common primary malignant bone tumor in adolescents and children,characterized by a high recurrence rate and metastasis,making its treatment extremely challenging.Traditional treatment modalities,including surgery,radiation therapy,and chemotherapy,can alleviate symptoms to some extent,but improving long-term survival rates remains a pressing issue.With the continuous development of immunotherapy,breakthroughs have been made in the research of tumor immune microenvironment and the application of immunotherapy in recent years,providing new perspectives and strategies for osteosarcoma treatment.Currently,immunotherapy strategies include tumor vaccines,targeted cytokines,immune checkpoint inhibition,adoptive cell therapy,combination therapy,etc.,significantly enhancing patient immune responses from the aspects of boosting immunity,overcoming immune tolerance,and preventing immune evasion,thereby effectively improving the patients'survival rates and prognosis.This review aims to systematically introduce the immune microenvironment of osteosarcoma and discuss the latest advances in immunotherapy in clinical translational research of osteosarcoma.By deeply understanding the immune characteristics of osteosarcoma and corresponding treatment methods,it is hopeful to provide more effective strategies for personalized treatment,contributing to the improvement of the patients' survival rates and prognosis.
